JPMorgan is scapegoating her with its fraud suit, Frank founder says
The dispute centers on conflicting narratives regarding JPMorgan’s acquisition of Frank, highlighting significant gaps in financial due diligence. JPMorgan alleges fraud by claiming the founder inflated user data, while the founder counters that the bank demanded synthetic metrics to assess user engagement, implying their own oversight failure. This clash reveals how sophisticated institutions may struggle to validate digital assets, raising concerns about the reliability of standard acquisition vetting processes in the tech sector. Frank’s case underscores the ambiguity surrounding data valuation in digital platforms. The disagreement over whether aggregated engagement metrics constitute valid customer data illustrates the challenges in defining intellectual property and user bases for fintech companies. It suggests that without clear industry standards, acquisitions involving large-scale user data can become legally contentious, particularly when privacy restrictions prevent direct access to raw user information during negotiations. This article is relevant to open data because it exposes the tension between proprietary business data and public transparency. The use of synthetic data to bridge privacy gaps offers a potential model for maintaining utility without exposing sensitive user information. However, it also serves as a cautionary tale about the need for rigorous, open auditing methods in data-driven transactions to prevent disputes over data integrity and to ensure that financial institutions can accurately assess the true value and security of the data they acquire.
Source: americanbanker.comPublished on 2023-03-01
Related news
- Public Records Request Nets User's Manual For Palantir's Souped-Up Surveillance Software
- Two Norwalk Dems allege Council majority violates open meeting laws
- Política de Privacidad
- FDA sued for concealing information about children's off-label use of puberty blockers, cross-sex hormones
- Shedding light on rare diseases: open data and model organisms